Natalizumab in the treatment of multiple sclerosis. Experience of the Moscow Multiple Sclerosis Center (MMSC)
A definite progress has been achieved in the treatment of patients with multiple sclerosis so far. However, first-line MS disease-modifying medications (MSDMM) do not always contribute to the stabilization of the autoimmune process. Second-line medications, including natalizumab, are successfully us...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2014-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/658 |